Oxford Biomedica CEO John Dawson to step down
Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
FTSE 250
20,378.03
09:05 23/12/24
n/a
n/a
FTSE 350
4,456.12
09:05 23/12/24
n/a
n/a
FTSE All-Share
4,414.00
09:05 23/12/24
n/a
n/a
Oxford Biomedica
425.50p
09:00 23/12/24
-0.23%
-1.00p
Pharmaceuticals & Biotechnology
19,879.17
09:05 23/12/24
0.60%
118.05
Dawson said he would "retire at the appropriate time".
"I believe this is the right time to start the transition to a new leader given the robustness of the senior team and company as a whole, which is undoubtedly stronger than ever before," he said in a statement.
Oxford Biomedica chairman Dr Roch Doliveux said it had started searching for Dawson's replacement to "lead the group through its next phase of growth".